As Lilly expands its India business in areas including obesity and cardiometabolic health, Ricks says the country can play a bigger role in discovering, developing and scaling medicines for global markets.

As American pharma giant Eli Lilly expands its India footprint, including in obesity and cardiometabolic disease, CEO Dave Ricks said India can play a bigger role in the global development of medicines, moving beyond its traditional strength in manufacturing.

More https://bit.ly/4rFhRxy

Via bharattoday.in